Higher US generic user fee for foreign units 'discriminatory, anti-competitive' charge Indian firms
This article was originally published in Scrip
Executive Summary
Indian firms believe that the US FDA's proposed generic drug user fee plan, under which foreign facilities will be required to pay more for inspections, is discriminatory and unwarranted.